Roy Vergis
The Royal Marsden NHS Foundation Trust
6 Papers
45 Citations
Roy Vergis is an academic researcher from The Royal Marsden NHS Foundation Trust. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 4, co-authored 5 publications. Previous affiliations of Roy Vergis include Institute of Cancer Research.
Chat about Author
Papers
Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.
Roy Vergis,Catherine M. Corbishley,Andrew R. Norman,Jaclyn Bartlett,Sameer Jhavar,Michael Borre,Sara Heebøll,Alan Horwich,Alan Horwich,Robert Huddart,Robert Huddart,Vincent Khoo,Ros Eeles,Ros Eeles,Colin Cooper,Matthew R. Sydes,David P. Dearnaley,David P. Dearnaley,Chris Parker,Chris Parker +19 more
TL;DR: This is the largest study of intrinsic markers of hypoxia and angiogenesis in relation to the outcome of radical treatment of localised prostate cancer and identifies patients at high risk of biochemical failure who would be suitable for enrolment into trials of treatment intensification.
300
Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer
Alison Reid,Alison Reid,Gerhardt Attard,Gerhardt Attard,Daniel Brewer,Susana Miranda,Ruth Riisnaes,Jeremy Clark,Lucy Hylands,Sue Merson,Roy Vergis,Charles Jameson,Søren Høyer,Karina Dalsgaard Sørenson,Michael Borre,Chris Jones,Johann S. de Bono,Johann S. de Bono,Colin Cooper +18 more
TL;DR: Gross rearrangements of the PTEN locus occur in prostate cancer and can be detected by a ‘break-apart’ FISH assay, which could explain the absence of PTEN protein expression in a subgroup of tumours previously classified as having heterozygous genomic loss using single-probe traditional FISH assays.
50
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
Janet E. Brown,Kara-Louise Royle,Walter M Gregory,Christy Ralph,Anthony Maraveyas,O.S. Din,Tim Eisen,Paul Nathan,Thomas Powles,Richard Griffiths,Robert Jones,Naveen S. Vasudev,Matthew Wheater,A. Hamid,T. Waddell,Rhona McMenemin,Poulam M. Patel,James Larkin,Guy Faust,Jayne Swain,Janine C Bestall,Christopher McCabe,David M. Meads,Vicky Goh,Tze Min Wah,Julia Brown,Jenny Hewison,Peter Selby,Fiona Collinson,Judith E. Carser,Gopalakrishnan Srinivasan,Fiona Thistlewaite,Ashraf Azzabi,Mark Beresford,David Farrugia,Marios P. Decatris,Carys Thomas,Joanna Gale,J. J. McAleer,A. Clayton,Ekaterini Boleti,T. Geldart,Santhanam Sundar,Jason F. Lester,Nachi Palaniappan,Mohan Hingorani,Khaliqur Rehman,Mohammad Emrul Hasan Khan,Naveed Sarwar,Janine Graham,Alastair M. Thomson,Narayanan Srihari,D. Sheehan,Rajaguru Srinivasan,O. Khan,Andrew Stockdale Jane Worlding,Stergios Boussios,N Stuart,Carey F MacDonald-Smith,F. Danwata,Duncan McLaren,Aravindhan Sundaramurthy,Anna Lydon,Sharon Beesley,Kathryn Lees,Mohini Varughese,Emma Gray,Angela Scott,Mark Baxter,Anna Mullard,Pasquale F. Innominato,Gaurav Kapur,Ashok Kumar,Natalie Charnley,C. Manetta,Prabir Chakraborti,Prantik Das,Sarah Rudman,H. Taylor,Christos Mikropoulos,Martin Highley,D Muthukumar,Anjali Zarkar,Roy Vergis,Seshadri Sriprasad,P. Brulinski,Amanda Clarke,R.D. Osbourne,Melanie Harvey,Renata Dega,G. Sparrow,Urmila Barthakur,E. Beaumont,Agnieszka Michael,Emilio Porfiri,Faisal Azam,Ravi Kodavtiganti +96 more
TL;DR: In this article , the authors compared a drug-free interval strategy with a conventional continuation strategy for first-line treatment of advanced clear cell renal cell carcinoma (CRC) patients.
37
Expression of Bcl-2, p53, and MDM2 in Localized Prostate Cancer With Respect to the Outcome of Radical Radiotherapy Dose Escalation
Roy Vergis,Catherine M. Corbishley,Karen Thomas,Alan Horwich,Robert Huddart,Vincent Khoo,Ros Eeles,Matthew R. Sydes,Colin Cooper,David P. Dearnaley,Chris Parker +10 more
TL;DR: Bcl-2 expression was a significant, independent determinant of biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for prostate cancer, and the hypothesis that Bcl-1 expression could be used to inform the choice of radiotherapy dose in individual patients is generated.
33
An improved method for constructing tissue microarrays from prostate needle biopsy specimens.
Frank McCarthy,A Fletcher,Nening Dennis,Craig Cummings,H O’Donnell,Jeremy Clark,Penny Flohr,Roy Vergis,Sameer Jhavar,Chris Parker,Colin Cooper +10 more
TL;DR: The construction of biopsy TMAs provides an effective method for the multiplex analysis of IHC and FISH markers and for their assessment as prognostic biomarkers in the context of clinical trials.
12